Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Resistance to Use of Contract MRs Weakening: Fuji-keizai Survey
December 8, 2003
- WORLD NEWS IN BRIEF
December 8, 2003
- BUSINESS NEWS IN BRIEF
December 8, 2003
- We Wish to Become a Global Mega-Player after 2005: Dr Aoki of Fujisawa
December 8, 2003
- Approval of 3 Drugs Including Atazanivir Recommended
December 8, 2003
- Semi-annual Business Result
December 8, 2003
- ICH-6 in Osaka Focuses on New Horizons and Future Challenges (2)
December 8, 2003
- Non-consolidated Sales of 29 Top Companies Down 0.3%
December 8, 2003
- REGULATORY NEWS IN BRIEF
December 8, 2003
- Alfresa Holdings: Fukujin, Azwell Show Mixed Results
December 8, 2003
- BULLETIN
December 8, 2003
- Astis: Consolidated Sales Down 2.1% at \43,756 Mil.
December 8, 2003
- Basic Policy on National Hospital Organization Issued
December 8, 2003
- Toho: Sales Up 17.4%, Net Profits Up 44.9%
December 1, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
December 1, 2003
- Takeover of Nikken Chemicals to Make Kowa Strengthen Marketing, R&D: President Miwa
December 1, 2003
- Global Standard Drugs to Be Covered by Special Medical Expenditure System during Application
December 1, 2003
- BUSINESS NEWS IN BRIEF
December 1, 2003
- Mutual GMP Recognition Discussed: MOSS Followup Talks
December 1, 2003
- PRESS SEMINAR
December 1, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…